New Guidelines to Evaluate Early Thin Melanoma

Created by:

18 Sep 2016 - General

  In order to avoid tests that offer no benefit, The American Society for Clinical Pathology has recommended against using sentinel lymph node biopsy or other diagnostic tests for the evaluation of early, thin melanoma. Sentinel lymph node biopsy (SLNB) is a minimally invasive staging procedure developed to identify patients with subclinical nodal metastases at higher risk of occurrence, who could be candidates for complete lymph node dissection or adjuvant systemic therapy. The National Comprehensive Cancer Network (NCCN) Melanoma Panel does not recommend SLNB for patients with in situ melanoma (stage 0). In general, the panel does not recommend SLNB for Stage 1A or 1B lesions that are very thin (0.75mm or less). In the rare event that a conventional high-risk feature is present, the decision about SLNB should be left to the patient and the treating physician. 

Mahmoud AbdelAziz Melanoma is a very rare disease in the Philippines. According to the World Healh Organization report released last 2012, there are approximately 300 Filipinos diagnosed every year. Although it is rare, the mortality rate is high at 50% because of the aggressive nature of this disease. In fact I only had two patients with melanoma, both of them foreign nationals. One was from Papua New Guinea an...
 (Total 140 words)